Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have received a consensus rating of “Hold” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $5.8333.

A number of brokerages recently issued reports on ZNTL. Guggenheim upped their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a report on Friday, April 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Tuesday, April 7th. Wells Fargo & Company began coverage on shares of Zentalis Pharmaceuticals in a report on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price objective for the company. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd.

Zentalis Pharmaceuticals Trading Down 0.5%

Shares of ZNTL opened at $3.98 on Tuesday. Zentalis Pharmaceuticals has a 12-month low of $1.13 and a 12-month high of $6.95. The firm has a 50-day moving average price of $3.78 and a 200 day moving average price of $2.70. The firm has a market capitalization of $283.34 million, a P/E ratio of -2.30 and a beta of 1.97.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). Equities research analysts predict that Zentalis Pharmaceuticals will post -1.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. 5AM Venture Management LLC lifted its position in Zentalis Pharmaceuticals by 705.7% in the fourth quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock valued at $5,330,000 after buying an additional 3,457,913 shares during the last quarter. Millennium Management LLC lifted its position in Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after buying an additional 2,111,951 shares during the last quarter. Vanguard Group Inc. lifted its position in Zentalis Pharmaceuticals by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after buying an additional 19,768 shares during the last quarter. Renaissance Technologies LLC lifted its position in Zentalis Pharmaceuticals by 24.0% in the fourth quarter. Renaissance Technologies LLC now owns 2,883,745 shares of the company’s stock valued at $3,893,000 after buying an additional 558,390 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Zentalis Pharmaceuticals by 117.1% in the third quarter. Bank of America Corp DE now owns 1,548,781 shares of the company’s stock valued at $2,339,000 after buying an additional 835,466 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.